Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palbociclib - Onyx Pharmaceuticals/Pfizer

Drug Profile

Palbociclib - Onyx Pharmaceuticals/Pfizer

Alternative Names: Ibrance; Iburance; Parvociclib; PD-0332991; PD-332991; PD-991; PF-332991

Latest Information Update: 12 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Onyx Pharmaceuticals; Pfizer
  • Developer Alliance Foundation Trials; Assistance Publique Hopitaux de Paris; Bergonie Institute; Calithera Biosciences; Canadian Cancer Trials Group; Celgene Corporation; Dana-Farber Cancer Institute; Emory University; European Organisation for Research and Treatment of Cancer; Georgetown University; German Breast Group; GlaxoSmithKline; Grupo Espanol de Tumores Neuroendocrinos; International Breast Cancer Study Group; iOMEDICO AG; Karolinska Institute; National Cancer Institute (USA); Northwestern University; Pfizer; UNC Lineberger Comprehensive Cancer Center; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclopentanes; Ketones; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II/III Non-small cell lung cancer
  • Phase II Bone metastases; Brain metastases; Gastrointestinal stromal tumours; Mantle-cell lymphoma; Pancreatic cancer; Prostate cancer; Squamous cell cancer; Urogenital cancer
  • Phase I/II Cancer; Colorectal cancer; Malignant melanoma
  • Phase I Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • No development reported Glioblastoma; Multiple myeloma
  • Discontinued Astrocytoma; Glioma

Most Recent Events

  • 22 Aug 2019 Registered for Breast cancer (Metastatic disease, Late-stage disease, Combination therapy, First-line therapy) in China (PO)
  • 31 Jul 2019 Preregistration for Breast cancer (Combination therapy, Late-stage disease, First-line therapy, Metastatic disease) in China (PO)
  • 02 Jul 2019 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (PO) (NCT03965845)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top